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Executive Summary 
Less than a century ago, cervical cancer was the number one cancer killer of women in 
the U.S. With the advent of the Pap test in the 1940s, cervical cancer became a largely 
preventable disease. Incidence and mortality rates for cervical cancer have fallen significantly 
since that time, but the disease has yet to be eliminated. The American Cancer Society has 
estimated that approximately 9,710 cases of invasive cervical cancer will be diagnosed and 3,700 
women will die from cervical cancer in the U.S. in 2006. The Maine Cancer Registry reports that 
58 women in Maine were diagnosed with invasive cervical cancer in 2003, and 15 women in 
Maine died from the disease in that year. 
While Maine has done relatively well with respect to cervical cancer prevention and early 
detection efforts and while cervical cancer incidence and mortality rates in Maine are comparable 
to national rates, the fact that this preventable disease exists at all is evidence that more can be 
done. Recognizing the opportunity for the State to make significant progress toward complete 
eradication of cervical cancer, the 12211 d Legislature established the Task Force to Study Cervical 
Cancer Prevention, Detection and Education ("Task Force") by Resolves 2005, Chapter 121. 
The Task Force was specifically created to examine the prevalence and incidence of cervical 
cancer in Maine, to review preventive strategies and new technologies, to assess existing laws, 
programs and services, and to develop a statewide cervical cancer prevention plan and strategies 
for plan implementation and coordination. 
The 16-member Task Force included one member of the Senate, two members of the 
House of Representatives, eight members representing different medical organizations, 
associations and specialties, one member representing the health insurance industry, one member 
representing communications consultants, one member representing cervical cancer survivors 
and two representatives of the Maine Department of Health and Human Services. The Task 
Force convened on November 16, 2005 and held a total of 6 meetings to fulfill its duties. The 
final meeting was held on October 17, 2006. 
Summary of Task Force Recommendations 
• Increase public awareness and education regarding cervical cancer prevention, the 
connection between the human papillomavirus and cervical cancer, and the 
importance of screening. Strategies include a statewide public education campaign 
on cervical cancer prevention and screening undertaken by the Maine Breast and 
Cervical Health Program and school-based cervical cancer education initiatives 
developed by the Maine Center for Disease Control and Prevention in coordination 
with the Maine Department of Education. 
• Increase provider knowledge of cervical cancer screening guidelines and emerging 
technologies in cervical cancer prevention and early detection. Strategies include 
expanding continuing medical education offerings for medical professionals that 
address clinical issues in cervical cancer prevention and detection and updating the 
Maine Breast and Cervical Health Program's clinical guidelines for cervical cancer 
screening. 
• Increase the number of Maine women who receive cervical cancer screening at 
recommended intervals. Strategies include expanding access to screening for low-
income and uninsured women through the Maine Breast and Cervical Health Program 
and the state family planning system, providing incentives for insured individuals to 
get screened for cancer, and implementing systems to assist and support health care 
providers in the delivery of cervical cancer screening consistent with clinical 
guidelines. 
• Implement the recommendations of the United States Centers for Disease Control 
and Prevention for the new hu1nan papillomavirus vaccine. Strategies include 
increasing state funding to the Maine Immunization Program, monitoring the 
vaccination rate and funding needs of that program and providing coverage for the 
vaccine under the state's MaineCare (Medicaid) program. 
• Conduct public health research to improve and evaluate cervical cancer prevention 
efforts. Strategies include examining cervical cancer incidence and prevention issues 
among racial and ethnic minority populations in Maine, examining geographic 
variation in cervical cancer within the State and the higher rates of cancer in Somerset 
and Washington Counties, and, finally, conducting an evaluation of the state's 
progress in cervical cancer prevention, detection and education in response to the 
work of this Task Force. 
ii 
I. INTRODUCTION 
The Task Force to Study Cervical Cancer Prevention, Detection and Education was 
established in the First Regular Session of the 122nd Legislature by Resolves 2005, Chapter 121. 1 
The Task Force was created to examine the prevalence and incidence of cervical cancer in 
Maine, to review preventive strategies and new technologies, to assess existing laws, programs 
and services, and to develop a statewide cervical cancer prevention plan and strategies for plan 
implementation and coordination. Specifically, the Task Force was charged with the following 
six duties: 
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer 
in Maine; 
2. Review preventive strategies and new technologies, including newly introduced vaccines 
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as 
their relative costs; 
3. Identify and examine the strengths and limitations of existing laws, regulations, programs 
and services regarding coverage and awareness of cervical cancer; 
4. Consider reports and testimony from individuals, local health depatiments, community-
based organizations, voluntary health organizations and other public and private 
organizations statewide to learn more about their contributions to cervical cancer 
diagnosis, prevention and treatment and their ideas for improving prevention, diagnosis 
and treatment in Maine; 
5. Develop, in consultation with the Department of Health and Human Services, a statewide 
comprehensive cervical cancer prevention plan and strategies for plan implementation 
and for promoting the plan and awareness of the causes, risk factors, prevention, early 
detection and treatment of cervical cancer to the general public, state and local elected 
officials and various public and private organizations, associations, businesses, industries 
and agencies; and 
6. Recommend strategies for coordination and communication among state and local 
agencies and organizations regarding their involvement in achieving the aims of the 
cervical cancer prevention plan. 
The 16-member Task Force included one member of the Senate, two members of the 
House of Representatives, eight members representing different medical organizations, 
associations and specialties, one member representing the health insurance industry, one member 
representing communications consultants, one member representing cervical cancer survivors 
and two representatives of the Maine Department of Health and Human Services (DHHS).2 
1 Resolves 2005, Chapter 121 is provided in Appendix A. 
2 The Task Force Membership list is provided in Appendix B. The position representing the Maine Osteopathic 
Association has been vacant in 2006. 
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Appointments to the Task Force were completed on October 19, 2005, and the Task 
Force convened for its first meeting on November 16, 2005. At the first meeting, members 
discussed the motivation for the study and identified the following justifications for undertaking 
this work: 
• While Maine is doing relatively well in the areas of cervical cancer prevention, 
detection and education, there is an opportunity for the State to further reduce the 
rate of cervical cancer given the current technology and to move toward complete 
eradication of cervical cancer with the development and introduction of new 
technology, and 
• There are gaps in the current system of cervical cancer prevention, detection and 
education in the State that need to be addressed. 
To fulfill its duties, the Task Force held a total of 6 meetings between November 2005 
and October 2006.3 The Task Force submitted an initial report to the Joint Standing Committee 
on Health and Human Services and the Governor in December 2005. The present report is the 
final report of the Task Force. Pursuant to Resolves 2005, chapter 121, the joint standing 
committee of the Legislature having jurisdiction over health and human services matters in the 
First Regular Session of the 123 rd Legislature is authorized to report out legislation on cervical 
cancer prevention, detection and education. 4 
3 Meeting dates were: November 16, 2005; December 20, 2005; July 18, 2006; August 24, 2006; September 26, 
2006; and October 17, 2006. Agendas for the Task Force meetings are provided in Appendix C. In accordance with 
the authorizing legislation, the Task Force did not meeting during the 2006 Legislative session. 
4 Draft legislation to implement the recommendations of the Task Force is provided in Appendix D. 
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II. CERVICAL CANCER INCIDENCE 
Less than a century ago, cervical cancer was the number one cancer killer of women in 
the U.S.5 With the advent of the Pap test in the 1940s, cervical cancer became a largely 
preventable disease. Incidence and mortality rates for cervical cancer have fallen significantly 
since that time, but the disease has yet to be eliminated. The American Cancer Society has 
estimated that approximately 9,710 cases of invasive cervical cancer will be diagnosed and 3,700 
women will die from cervical cancer in the U.S. in 2006.6 
Cervical cancer incidence rates and mortality rates for Maine are similar to those for the 
U.S. white population, particularly in recent years (see Figure 1 and Figure 2).7 In 2003, the 
approximately 8 per 100,000 women in Maine (58 women statewide) were diagnosed with 
invasive cervical cancer, and 1.8 per 100,000 women in Maine died from the disease (15 deaths 
statewide). 
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5 
"Cervical Cancer Prevention and HPV DNA Test," Health & Sexuality 19(1) 2005. 
6 American Cancer Society, "Detailed Guide: Cervical Cancer," Revised August 2006, 
http:/ /www.cancer.org/docroot/cri/cri_ 2 _ 3x.asp?dt=8 
7 The difference between cervical cancer incidence and mortality rates for Maine and U.S. whites are not statistically 
significant. The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) collects cancer 
information from 13 population based registries representing approximately 14% of the U.S. Population; because the 
Maine population is 98% white, the Maine Cancer Registry uses the SEER U.S. white population data as a national 
companson. 
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Figure 2 -Age-Adjusted Cervical Cancer Mortality Rates, 1990-2003 
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The incidence of invasive cervical cancer increases dramatically among women in their 
mid-20s and early 30s (see Figure 3). This is consistent with the scientific evidence that cervical 
cancer develops over a relatively long period of time following exposure to HPV (typically 10-15 
years ifHPV or precancerous cells are not detected or treated). The incidence of invasive 
cervical cancer among Maine women peaks for women ages 40-44 years and again for women 
ages 70-7 4 years. This data suggests that targeting prevention efforts toward Maine girls and 
young women would prove effective in decreasing cervical cancer incidence in the future. The 
data also provide an important reminder that women over 60 years of age should not be neglected 
in prevention and early detection efforts. 
Figure 3- Age-Specific Cervical Cancer Incidence Rates, 1995-2003 
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Within Maine, the highest rates of invasive cervical cancer are found in two 
geographically separate areas: Somerset County in western Maine and Washington County in 
eastern Maine (see Table 1). The age-adjusted incidence rates in these two counties are 
significantly higher than the statewide rate. While the differences are not statistically significant, 
lower rates of invasive cervical cancer are observed in southern and mid-coast counties, 
including Cu1nberland, York, Sagadahoc and Knox counties. 
Table 1 -Age-Adjusted Cervical Cancer Incidence Rates by Maine County, 1995-2003 
Age 
Adjusted 
9-Year Rate per 
County Count 100,000 
Androscoggin 43 8.7 
Aroostook 33 9.0 
Cumberland 82 6.2 
Franklin 12 8.6 
Hancock 26 10.2 
Kennebec 50 8.6 
Knox 13 6.0 
Lincoln 15 9.0 
Oxford 33 11.9 
Penobscot 75 10.7 
Piscataquis 6 7.2 
Sagadahoc 9 5.5 
Somerset 38 15.6 
Waldo 21 11.4 
Washington 26 15.0 
York 59 6.4 
Maine 542 8.6 
Source: Maine Cancer Registry. 
Although racial and ethnic minority populations in Maine are presently too small to allow 
for statistical analysis of racial and ethnic differences in cervical cancer within the state (and 
guarantee the confidentiality of individuals), these populations are growing and such analysis will 
likely be possible in the future. National data provide clear evidence of variation in cervical 
cancer incidence by race and ethnicity. In 2002, the incidence rate per 100,000 was 8.2 among 
white women in the U.S., 12.4 among Black women and 13.1 among Hispanic women.8 
Historically, Vietnamese American women have had the highest rates of cervical cancer, at 
approximately five times the national rate ( 43 per 100,000 women during the period 1988-
1992).9 
8 National Cancer Institute, State Cancer Profiles, 2002, http://statecancerprofiles.cancer.gov 
9 President's Advisory Commission on Asian Americans and Pacific Islanders, "Asian Americans and Pacific 
Islanders Addressing Health Disparities: Opportunities for Building a Healthy America," 2003, 
http://www.aapi.gov/Commission_Final_Health_Report.pdf 
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Ill. PREVENTION STRATEGIES AND NEW TECHNOLOGIES 
A. Cervical Cancer Screening 
Cervical cancer is a highly preventable disease through regular screening. The 
cornerstone of prevention for the last 60 years has been the Pap test. Developed by Dr. George 
Papanicolaou, the Pap test is credited for producing a greater than 70% drop in the death rate 
from cervical cancer since its introduction. 10 In 2004, nearly 89o/o of Maine women reported 
having had a Pap test within the last three years, 3 percentage points higher than the national 
median of 86o/o. 11 In addition to the Pap test, human papillomavirus (HPV) testing technology 
has recently emerged as an additional tool for cervical cancer screening. 
1. Pap Testing 
The Pap test is used to detect abnormal changes in cervical cells that may lead to the 
development of cervical cancer. Today, there are two key Pap test technologies: (1) the 
conventional Pap smear, which involves "smearing" cervical cells onto a glass slide, and (2) the 
newer thin-layer liquid-based Pap test approved by the FDA in 1996, which involves placing a 
sample of cervical cells in liquid. 12 The newer liquid-based technology has proven to have 
several advantages over the conventional Pap, including: higher quality sample; greater 
effectiveness in detecting low-grade and high-grade intraepitheliallesions; and the ability to 
conduct follow-up HPV testing without requiring the patient to return for another procedure. 
Given these advantages, health care providers are increasingly choosing to use the liquid-based 
Pap test over of the conventional Pap test. It is important to note that the liquid-based test is 
more expensive, because of the associated laboratory work. 13 
The state of Maine requires coverage for Pap tests through both law and program 
regulations. In the case of private health insurance, state law requires that all group health 
insurance policies and health maintenance organization (HMO) contracts cover "screening Pap 
tests recommended by a physician."14 Under the state Medicaid program, MaineCare, the Pap 
test procedure and associated laboratory services are covered, except that laboratory services are 
not covered for women in program's the "non-categorical" eligibility category (non-disabled, 
childless adults). 15 Under the Maine Breast and Cervical Health Program, Pap tests are covered 
for participating women (see section IV of this report for details on this program). 
10 
"Cervical Cancer Prevention and HPV DNA Testing," Health & Sexuality 10(1) 2005 
11 U.S. CDC, Behavioral Risk Factor Surveillance System (BRFSS), http://apps.nccd.cdc.gov/brfss/ 
12 
"Human Papilloma Virus Testing in Cervical Cancer Prevention," Medscape, 
http://www.medscape.com/viewarticle/467126_6 
13 The two largest independent laboratories serving Maine currently charge $37.10-$42.00 for the liquid-based test 
and $22.80-$25.00 for the conventional Pap. Source: Maine DHHS. 
14 24-A MRSA §§2837 and 4242. 
15 See MaineCare Benefits Manual sections on Physician Services (Chapters II and III, Section 90), Family Planning 
Agency Services (Chapters II and III, Section 30), and Laboratory Services (Chapters II and III, Section 55). See 
also Non-categorical Adults List of Covered Services (Chapter I, Appendix 3). 
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2. HPV Testing 
HPV testing is increasingly being used to augment Pap testing in the diagnosis of cervical 
cancer. The HC2 High-Risk HPV DNA test manufactured by Digene Corporation (HPV test) 
was first approved by the U.S. Food and Drug Administration (FDA) in 2000 for use in the 
evaluation of abnormal Pap tests results. 16 At that time, the test was specifically indicated for use 
following an abnormal Pap to determine whether to proceed to a colposcopy, a procedure in 
which the outer portion of the cervix is examined using an instrument called a colposcope to 
magnify and illuminate the area. In 2003, the FDA approved expanded use of the HPV test in 
women over 30 years. Specifically, it approved the use of this test in primary screening of 
women over 30 years for cervical cancer, when used in conjunction with the Pap test. 17 Used in 
this way, the HPV test presents the opportunity to extend the cervical cancer screening intervals 
for women over 30 years with negative Pap tests and negative HPV tests. 
3. Screening Guidelines 
Cervical cancer screening guidelines are provided by three national medical 
organizations: (1) the American Cancer Society (ACS), (2) the U.S. Preventive Services Task 
Force18 (USPSTF), and (3) the American College of Obstetricians and Gynecologists (ACOG). 
As shown in Table 2, the recommended starting point for screening is similar across the three 
guidelines, but the guidelines different somewhat regarding the time between screening tests, 
screening interval, and when to stop screening. While annual screening is common practice 
today, it is important to note that the guidelines advise less frequent screening in specific 
situations. 
4. Cervical Cancer Screening Failure 
Given the existing screening technology, it is estimated that 95% of cervical cancer could 
be prevented under perfect conditions. 19 In reality, 30o/o of cervical cancer cases are not 
prevented as a result of imperfections, or failures, in the screening system. Screening failures can 
be divided into two major types: 
1. Insufficient screening. Approximately 65-70% of screening failures are the result of 
women not being screened. This includes women who have never been screened and 
women who are screened less frequently than is recommended, and 
2. False negative screening. Approximately 30-35% of screening failures are the result of 
"false negative" screening, in which a woman is screened but still develops cervical 
cancer. 
16 U.S. Food and Drug Administration, http://www.fda.gov/cdrh!pdf/P890064s009b.pdf 
17 U.S. Food and Drug Administration, http://www.fda.gov/cdrh!pdf/p890064s009a.pdf 
18 The USPSTF, sponsored by the U.S. DHHS Agency for Healthcare Research and Quality (AHRQ), is an 
independent panel of experts in primary care and prevention that reviews the scientific evidence of effectiveness and 
develops recommendations for clinical preventive services. 
19 Presentation of Dr. Michael Jones to the Task Force on December 20, 2005. 
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Table 2 - Cervical Cancer Screening Guidelines20 
U.S. Preventive American College of 
American Cancer Services Task Force Obstetricians and 
Society (Jan. 2003) Gynecologists 
Recommendation (Nov. 2002) (Aug. 2003) 
When to Start Screening Approximately 3 Within 3 years of Approximately 3 
years after onset of onset of sexual years after onset of 
vaginal intercourse, activity or age 21, sexual intercourse, but 
but no later than age whichever comes first no later than age 21 
21 
Screening Interval 
If conventional Pap smear test a) Annually At least every 3 years a) Annually 
b) Every 2-3 years for b) Every 2-3 years for 
women ?::30 yrs with 3 women ?::30 yrs with 3 
negative cytology negative cytology 
tests tests 
If liquid-based cytology test a) Every 2 years Insufficient evidence a) Annually 
b) Every 2-3 years for b) Every 2-3 years for 
women ?::30 yrs with 3 women ?::30 yrs with 3 
negative cytology negative cytology 
tests tests 
If HPV testing used Every 3 years if HPV Insufficient evidence Every 3 years if HPV 
negative, cytology negative, cytology 
negative negative 
When to Stop Screening Women?:: 70 yrs with Women > 65 yrs with Inconclusive evidence 
?:: 3 recent, negative tests, who to establish upper age 
consecutive negative are not otherwise at limit 
tests and no abnormal high risk for cervical 
tests in prior 10 years cancer 
B. Cervical Cancer Vaccines 
The newest technology in the fight against cervical cancer is the HPV vaccine. Infection 
by HPV is well-established as the most important risk factor for cervical cancer, and research has 
shown the presence of HPV in over 93% of cervical cancers. 21 HPV is a very common infection. 
The U.S. Centers for Disease Control and Prevention (CDC) has estimated that 20 million people 
in U.S. were infected with HPV in 2005 and 80% of women have been infected by HPV by age 
50.22 Most HPV infections are transient and resolve on their own without medical intervention 
and do not develop into cervical cancer.23 However, when HPV does not go away on its own, 
20 
"Summary Tables of Cervical Cancer Screening Guidelines and Recommendations for New Technologies," U.S. 
Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention (CDC), 
http://www.cdc.gov/std/hpv/ScreeningTables.pdf 
21 National Cancer Institute. "Cervical Cancer: Backgrounder," 
http:/ /rex.nci. nih. gov /massmedia/backgrounders/ cervical.htrnl 
22 
"CDC's Advisory Committee Recommends Human Papillomavirus Virus Vaccination," U.S. CDC, 
http://www.cdc.gov/od/oc/media/pressrel/r060629.htm 
23 Presentation of Dr. Michael Jones to the Task Force on December 20, 2005. 
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certain types of the virus can develop into cervical cancer. There are more than 100 types of 
HPV, but only certain types have been linked to the development of cervical cancer, including 
HPV 16 which is estimated to account for 50% of cervical cancer, and HPV 18, 31 and 45, which 
together are estimated to account for 30o/o of cervical cancer.24 
Given the strong link between HPV and cervical cancer, vaccines that protect against 
HPV have the potential to play an important role in preventing cervical cancer, particularly 
among women who are not getting screened at the recommended intervals. It is important to 
note that even once vaccines are available, screening will remain critical to cervical cancer 
prevention for a number of reasons, including the fact that the vaccines do not protect against all 
strains of HPV that cause cervical cancer, the vaccines do not treat existing HPV infection, and 
there are many women today who will not receive the vaccines. It is also important to recognize 
that there will be a significant lag period between the introduction of HPV vaccines and a 
reduction in cervical cancer incidence and mortality rates, due to the latency associated with this 
cancer. Additionally, acceptance of the vaccines among health care providers and consumers is 
an important practical challenge that will need to be addressed to fully realize the potential of 
these vaccines. 
1. Gardasil 
On June 8, 2006, the FDA approved Gardasil, for use in females ages 9-26 for the 
"prevention of cervical cancer and other diseases caused by HPV." 25 ' 26 Manufactured by Merck 
and Co, Inc., Gardasil is the first vaccine approved by the FDA for cervical cancer prevention. 
Gardasil targets four types ofHPV: 6, 11, 16 and 18. HPV types 16 and 18 are leading causes of 
cervical cancer, accounting for 70% of all cervical cancer cases.27 
On the basis of Merck's clinical trials, involving 21,000 women worldwide, the FDA 
concluded that: 
Gardasil was nearly 100 percent effective in preventing precancerous cervical lesions, 
precancerous vaginal and vulvar lesions, and genital warts caused by infection with the 
HPV types against which the vaccine is directed. While the study period was not long 
enough for cervical cancer to develop, the prevention of these cervical precancerous 
lesions is believed highly likely to result in the prevention of those cancers.28 
24 Shah, Keerti V. (1997). "Human Papillomaviruses and Anogenital Cancers." The New England Journal of 
Medicine, 337(19) 1386-1388. 
25 
"FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human 
Papillornavirus," FDA, http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html 
26 Merck is currently conducting clinical trials with women aged 27-45 years and with men. Dr. Liana Clark, Merck, 
presentation to the Task Force, August 24, 2006. 
27 Merck is developing a vaccine that will cover 8 types of HPV; the company hopes to have that drug approved by 
2010. Dr. Liana Clark, Merck, presentation to the Task Force, August 24, 2006. 
28 
"FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human 
Papilloma virus," FDA, http:/ /www.fda.gov/bbs/topics/NEWS/2006/NEWO 13 85 .html 
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Following the FDA's approval ofGardasil on June 8, the CDC's Advisory Committee on 
Immunization Practices (ACIP) voted on June 29, 2006, to recommend routine vaccination with 
three doses of Gardasil for all girls ages 11-12 years, as well as "catch-up" vaccination of girls 
and women ages 13-26 years who have not received the vaccine or completed the 3-injection 
series. Routine vaccination at ages 11-12 years is designed to catch most girls prior to any 
exposure to HPV, so that the vaccine can have its maximal effect. These recommendations were 
posted by the CDC as "Provisional Recommendations" in August 2006 and final publication of 
the recommendations is expected in November 2006.29 
2. Cervarix 
GlaxoSmithKline (GSK) is currently seeking FDA approval for its HPV vaccine, 
Cervarix. Cervarix is a bivalent vaccine that targets HPV types 16 and 18. Phase III clinical 
trials of Cervarix are currently in progress, and GSK submitted its Biologics License Application 
(BLA) in 2006. Like Gardasil, Cervarix has been shown to be highly effective in preventing 
persistent HPV infection and HPV type-specific associated lesions. 30 
29 
"ACIP Provisional Recommendations for the Use ofQuadrivalent HPV Vaccine," U.S. CDC, 
http://www.cdc.gov/Nip/recs/provisional_recs/hpv.pdf 
30 Diane M. Harper, MD, MPH, MS. Presentation, Conference on "The Status of Cervical Cancer Vaccine 
Research", Women's Policy, Inc., Washington, DC, December 6, 2005. 
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IV. EXISTING PROGRAMS AND SERVICES 
The Task Force reviewed and examined the strengths and limitations of current programs 
and services in the State that contribute to cervical cancer prevention, detection and education. 
Through reports, presentations and discussions, the Task Force developed the following 
inventory of key state agencies and organizations involved in various aspects of cervical cancer. 
A. Maine Breast and Cervical Health Program 
The Maine Breast and Cervical Health Program (MBCHP) provides free cervical cancer 
(and breast cancer) screening and related diagnostic services for low-income and uninsured 
women in the state. This program operates within Maine DHHS under authorization and funding 
from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) of the U.S. 
CDC. The NBCCEDP, which was established by Congress under the Breast and Cervical Cancer 
Mortality Prevention Act of 1990, is the first and only national cancer screening program. Maine 
is one of over 60 states and tribal organizations that have received funding from the CDC to 
implement a comprehensive breast and cervical cancer health program. Key features of the 
program are as follows: 
• Funding. MBCHP currently receives nearly $1.8 million in annual funding from 
the U.S. CDC. These federal funds are supplemented with approximately 
$370,000 in state General Fund dollars. 
• Eligibility. Eligibility for MBCHP is based on age, income, insurance status and 
residence. Under current MBCHP rules, women who are 40 years and older, have 
income at or below 250% of the federal poverty level, are uninsured or 
underinsured, and reside in Maine or New Hampshire are eligible.31 
• Enrollment. Since its inception, MBCHP has enrolled over 16,700 women, 
provided 25,820 Pap tests and diagnosed 61 cases of cervical cancer, including 5 
cases of invasive cervical cancer and 56 cases of carcinoma in situ of the cervix. 32 
Current program enrollment is over 5,300 women, with approximately one-third 
age 40-49 years and the remaining two-thirds age 50 years and older.33 
Enrollment rates vary from 43% of eligible women in Washington County down 
to 7% of eligible women in Cumberland County. 34 
• Covered clinical services. For enrollees, the MBCHP provides an annual exam, 
including a clinical breast exam, pelvic exam and a Pap test. An HPV test is 
31 The U.S. CDC gives the option of eligibility starting at age 18; due to the limited funding for MBCHP and the 
availability of family planning services for younger women, Maine decided to begin eligibility at age 40. 
32 Carcinoma in situ is noninvasive; cancer cells are in the first layer of cells lining the cervix only and have not 
invaded the deeper tissues. Source: National Cancer Institute. 
33 As of October 6, 2006, MBCHP reports 5,329 women enrolled. 
34 Source: Maine Department of Health and Human Services, Maine Breast and Cervical Health Program. 
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covered following an abnormal result on a Pap test. Cancer treatment is not 
covered by MBCHP but, in most cases, is covered by MaineCare pursuant to the 
federal Breast and Cervical Cancer Prevention and Treatment Act of 2000. 
• Service delivery system and outreach. MBCHP funds more than 300 sites to 
provide clinical and educational services. These include: primary care provider 
sites which provide clinical exams and pap tests; other health care professionals 
who provide diagnostic services on referral; laboratory facilities that provide 
cytology and pathology services; and six community partnerships that provide 
public education and other support services in six counties. In 2005, the MBCHP 
distributed 70,000 brochures and 1,900 posters to 441 sites across the state. 
B. MaineCare and the Treatment Act 
Since 2001, Maine has provided Medicaid (MaineCare) coverage for cancer treatment to 
women diagnosed with cervical cancer, or breast cancer, under the MBCHP. This coverage was 
established in accordance with the federal Breast and Cervical Cancer Prevention and Treatment 
Act of2000 (the Treatment Act), through Maine Public Law 2001, chapter 439, Part TT, which 
required DHHS to amend its rules to provide full MaineCare coverage to eligible women 
diagnosed with breast or cervical cancer by the MBCHP. Approximately two years following 
this rule change, Maine applied for and received federal approval for a less restrictive option 
allowed under the federal Treatment Act, under which the state provides MaineCare coverage to 
eligible women who are not enrolled in MBCHP but who: (a) meet MBCHP eligibility 
requirements and (b) are screened or diagnosed at a participating MBCHP site. 35 
To be eligible for MaineCare under the Treatment Act provisions, a woman must be 
under age 65, not covered by credible health insurance, and have income less than 250% of the 
federal poverty level. 36 MaineCare coverage under these rules is continuous for at least one year 
as long as the woman is receiving cancer treatment. Since 2001, a total of 103 women with 
cervical cancer or pre-cancer have enrolled in MaineCare under these rules. 
C. Maine Cancer Registry 
The Maine Cancer Registry (MCR) has an important role in cervical cancer prevention as 
the source of statewide data and expertise regarding cancer incidence. The MCR was established 
by the Legislature in 1983 to provide a population-based cancer surveillance system for the 
state. 37 The registry, which operates within the Maine CDC, DHHS, receives federal funding 
35 This change was motivated by LD 143, Resolve, to Improve Access to Breast and Cervical Cancer Treatment, 
which was proposed in the 121 st legislature. Ultimately, LD 143 was not enacted after the department agreed to 
make the changes without legislation. 
36 Specifically the individual must have no "credible coverage" as defined in Section 2701(a) of the federal Public 
Health Service Act. 
37 22 MRSA § 1404. 
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under the National Program of Cancer Registries, a program of the U.S. CDC. These federal 
dollars are matched with state funds, at a ratio of $3 federal to $1 state. 
The MCR collects patient demographic, diagnosis and initial treatment data on cases of 
cancer diagnosed in Maine. With respect to cervical cancer, the MCR collects data on cases of 
invasive cervical cancer (cervical cancer that has invaded surrounding tissues); it does not collect 
data on cervical carcinoma in situ (noninvasive).38 The data is collected by MCR comes from 
hospitals, health care facilities, physicians and other health care providers who diagnose or treat 
cancer patients. The MCR law requires health care providers and facilities to report new cases of 
cancer within six months of diagnosis. 39 The MCR uses the data it collects to monitor and 
evaluate cancer trends in Maine, to identify areas in need of public health interventions and to 
improve cancer prevention, treatment and control. The MCR publishes an annual cancer 
incidence report that includes statistical comparisons between Maine and the nation for various 
cancer types, including invasive cervical cancer. 
D. Maine Immunization Program 
With the recent introduction of the HPV vaccine, the Maine Immunization Program 
(MIP) within DHHS is positioned to become an important player in the state's cervical cancer 
prevention efforts. Under its "universal purchase policy," Maine purchases and distributes to 
public and private health care providers statewide all of the CDC-recommended vaccines for all 
children aged 0 to 18 years, as well as influenza, pneumococcal and first dose measles, mumps, 
rubella for adults. Currently, the MIP distributes approximately 300,000 doses of vaccine 
annually to over 700 health care providers in the state.40 In addition to its vaccine purchase and 
distribution functions, the MIP also measures immunization rates, provides education and 
information regarding immunization issues, monitors vaccine usage and maintains an electronic 
immunization registry. 
Funding of the MIP emerged as an important issue of concern to the Task Force. The MIP 
currently receives funding to purchase vaccine from the following sources: 
• Vaccines for Children (VFC). Vaccines for Children is a federal entitlement program 
that provides vaccines recommended by the U.S. CDC's Advisory Council on 
Immunization Practices (ACIP) at no cost for children aged 0-18 years in the following 
categories: Medicaid-eligible; uninsured; insured but insurance does not cover childhood 
immunizations (these children must go to a Federally Qualified Health Clinic or Rural 
Health Clinic); and Native American or Alaskan Native. In 2005, the U.S. CDC awarded 
$3.2 million in VFC-purchased vaccines for Maine children who qualify for VFC. On 
38 The MCR also does not collect data on basal cell and squamous cell carcinoma of the skin. 
39 22 MRSA § 1402. 
40 Source: Maine Immunization Program, http://www.maine.gov/dhhs/bohlmip/vaccine _related.html 
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November 1, 2006, Merck announced that the U.S. CDC added Gardasil to the VFC 
contract.41 
• Section 317 Grant Program. The Section 317 program is a federal grant program that 
provides funding for vaccines for underinsured children not covered under VFC, and for 
adults. This is a discretionary annual appropriation at the federal level. In 2005, the U.S. 
CDC awarded $2.9 million in Section 317 funding to Maine. 
• Private Health Insurance Plans. Under an oral agreement between the State and six 
HMOs under the umbrella of the Maine Association of Health Plans, six HMOs make an 
annual contribution to support the state's purchase of vaccine for children.42 In 2005, the 
six HMOs contributed $700,000 to the state for vaccine purchase for children. 
• Fund for a Healthy Maine (FHM). Under a recent Maine law, certain FHM (tobacco 
settlement) dollars have been allocated specifically for the purchase of influenza vaccine 
for adults.43 In 2005, $1.2 million in FHM dollars were made available for this purpose. 
There is currently no General Fund support for the purchase and distribution of vaccines. The 
lack of General Fund support for this program poses a significant challenge to the MIP in its 
efforts to carry out the state's universal purchase policy. This challenge increases with each year 
as new vaccines are recommended, the prices for vaccines increase and federal appropriations for 
the Section 317 grant program fail to keep up with these recommendations.44 Even before the 
addition of the new HPV vaccine, the MIP has estimated that to cover 80% of Maine children 
with the CDC recommended vaccines, the program needs an additional $2.5 million per year for 
vaccines for children aged 0-10 years, and an additional $1.5 million for vaccines for children 
aged 11-18 years.45 
E. Maine Cancer Consortium 
The Maine Cancer Consortium was established in 1999 to develop and implement a state 
cancer control plan. Today, the consortium is a statewide partnership including 300 individuals 
representing over 130 public and private organizations. The Consortium relies on its members to 
seek and provide funding which comes from variety of public and private sources. Membership 
in the Consortium is open to anyone interested in its mission, which is "to reduce the burden of 
cancer in Maine by working collaboratively to optimize quality of life by improving access to 
care, prevention, early detection, treatment, rehabilitation, survivorship, palliation and end of life 
41 
"Product News: Merck's Cervical Cancer Vaccine, Gardasil®, Added to the CDC Vaccines for Children 
Contract," Merck, http:/ /www.merck.com/newsroom/press _releases/product/2006 _11 0 1.html 
42 The amount of the contribution is based on the HMO's self-reported number of children within specific age 
groups. 
43 PL 2003, c. 451, Pt RR. 
44 Cochi, Stephen L. MD, MPH. "Vaccine Financing from the National Immunization Program's Perspective," 
National Immunization Program, U.S. CDC, June 2004. 
45 Source: Maine Immunization Program, data provided to the Task Force, September 2006. 
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care."
46 The focus of the Consortium's work continues to be the development and 
implementation of the state cancer plan. In May 2006, the Consortium released the Maine 
Cancer Plan 2006-2010. The plan includes a specific section on cervical cancer, as well as a 
section on sexual health that addresses HPV prevention. 47 
F. Maine Comprehensive Cancer Control Program 
The Maine Comprehensive Cancer Control Program, or Comp Cancer, was established by 
the Legislature in 2003 to coordinate Maine's cancer control efforts, including prevention, 
research and treatment activities.48 Comp Cancer is a participating program of the U.S. CDC 
National Comprehensive Cancer Control Program, and is entirely supported by federal funds at 
this time. Current objectives of Comp Cancer include: expanding collaborative efforts in place 
through the Maine Cancer Consortium; increasing use of the Maine Cancer Plan; providing 
technical assistance to state and local organizations; conducting public awareness projects; and 
evaluating implementation of the Maine Cancer Plan. 49 In the area of screening, Comp Cancer 
has launched a public awareness campaign for colo rectal cancer screening. 50 
G. Family Planning Services 
The state family planning system has an important clinical and educational role in 
cervical cancer prevention. At the center of the system is the Family Planning Association of 
Maine (FP A), which was founded in 1970. The FP A is the Maine grantee for federal family 
planning funding under Title X of the Public Health Services Act. As the Title X grantee for the 
state, the FP A provides funding and assistance to a network of 11 delegate agencies that operate 
a network of 45 family planning clinic sites statewide, which provide comprehensive 
reproductive health services, including cervical cancer screening and related tests. In 2005, 
Maine family planning clinics served over 30,000 clients. More than half of these clients (52o/o) 
had income at or below the federal poverty level and just under half of the clients were 18 to 24 
years of age (46%). 51 In addition to clinical services, the FPA also provides outreach and 
education, including family life education programs, and works to advance the cause of 
reproductive freedom. 
The FPA is a private non-profit organization. In addition to federal funds, FPA receives 
state funds, including approximately $1.3 million from the General Fund to support clinical 
services and family life education and $0.4 million from the Fund for Healthy Maine to conduct 
outreach to high-risk populations. Additional revenue sources include fees, reimbursement by 
third-party insurance, private fund-raising, grants from private foundations, and investments. 
46 Maine Cancer Consortium, http://www.mainecancerconsortium.org/welcome.html 
47 These sections of the Maine Cancer Plan are provided in Appendix E. 
48 PL 2003, c. 215; 22 MRSA §1407. 
49 Maine Comprehensive Cancer Control Program, http://www.maine.gov/dhhs/bohlccc/index.htrn 
50 Screen Me materials can be viewed on line at http://www.maine.gov/dhhs/bohlccc/screenme.htrn 
51 Presentation of Evelyn Kietlyka, Family Planning Association of Maine, to the Task Force on August 24, 2006. 
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V. CERVICAL CANCER PREVENTION PLAN- RECOMMENDATIONS 
Based on its review and assessment of cervical cancer incidence, prevention technologies, 
the current array of programs and resources available in the state and the recommendations of the 
Maine Comprehensive Cancer Control Plan 2006-2010, the Task Force has developed its 
recommendations for a plan of action to eliminate cervical cancer in Maine. The Task Force 
recommendations, including specific actions and strategies, are organized around the following 
objectives: 
• Increase public awareness and education regarding cervical cancer prevention, the 
connection between HPV and cervical cancer, and the importance of screening; 
• Increase provider knowledge of cervical cancer screening guidelines and emerging 
technologies in cervical cancer prevention and early detection; 
• Increase the number of Maine women who receive cervical cancer screening at 
recommended intervals; 
• Implement the recommendations of the U.S. CDC for the new HPV vaccine; and 
• Conduct public health research to improve and evaluate cervical cancer prevention 
efforts. 
The Task Force recognizes that there are costs attached to each of its recommendations and 
further recommends that the State appropriate and allocate the funds necessary to implement its 
proposals, as outlined below. 
A. Public Awareness 
Objective: Increase public awareness and education regarding cervical cancer prevention, 
the connection between HPV and cervical cancer, and the importance of screening. 
Recommended strategies: 
1. Direct the Maine Breast and Cervical Health Program (MBCHP) to implement a 
statewide public education campaign on cervical cancer prevention and screening, as 
follows: 
a. Develop and distribute printed informational materials to all sites that 
currently receive MBCHP brochures, 52 plus additional locations statewide 
52 In 2005, MBCHP brochures were distributed to 441 sites, including DHHS offices, hospitals, primary care 
providers and mammography facilities. 
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including libraries, shopping malls, grocery stores, hair salons, pharmacies and 
health care facilities; offer these materials to faith-based organizations. 
b. Coordinate specific educational outreach initiatives for racial and ethnic 
minorities in the state, particularly in Portland, Lewiston, and Bangor, and 
develop multi-lingual fact sheets and informational materials, as appropriate. 53 
c. Collaborate with organizations representing senior citizens and retired persons 
to ensure the public awareness campaign reaches women over 60 years. 
d. Increase the broadcast of MBCHP public service announcements from the 
current 4 months (January-April) to all 12 months of the year. 
2. Direct the Maine CDC to implement school-based cervical cancer education 
initiatives, as follows: 
a. Develop printed educational materials appropriate for posting at middle and 
secondary schools and universities, including multi-lingual versions as 
appropriate. Partner with the Department of Education (DOE) and the 
University of Maine System to coordinate the distribution and posting of 
materials at public schools and universities. Include restrooms as a site for 
posting these materials. Offer the materials to private schools and 
universities. 
b. Develop an educational pamphlet for 5th grade students regarding the 
availability of the HPV vaccine. 54 Work with DOE health education staff, 
school nurses and health coordinators to facilitate distribution of the pamphlet 
in public schools. Provide copies of the pamphlet to all pediatricians and 
family physicians licensed in the state. Offer the pamphlet to private schools. 
c. Develop, in collaboration with DOE health education staff, a "speakers' 
network" consisting of medical professionals willing to speak about cervical 
cancer prevention in health education classes or other school forums. 
d. Seek grant funding to implement an activity-based cervical cancer education 
initiative in Maine schools. 55 
53 Cancer Care Ontario (Canada) has a fact sheet "HPV and Cancer of the Cervix" in English and 14 other languages. 
See for example: http:/ /www.cancercare.on.ca/pdf/ocsp _somali_ hpv.pdf (Somali) 
http:/ /www.cancercare. on. ca/pdf/FSHPVE. Q XD. pdf (English) 
54 Fifth grade was selected because the federal CDC recommendation is to begin vaccination at 11-12 years. 
55 See for example, the "Make the Connection" campaign and bracelet activity recently conducted by the Cancer 
Research and Prevention Foundation and Step Up Women's network, with support from Merck and Co.; see: 
www .maketheconnection. org 
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B. Provider Knowledge 
Objective: Increase provider knowledge of clinical guidelines for cervical cancer 
screening and emerging technologies in cervical cancer prevention and early detection. 
Recommended strategies: 
1. Direct the Maine CDC to work with the Maine Medical Association's Committee on 
Continuing Medical Education and Accreditation to increase continuing medical 
education (CME) offerings regarding cervical cancer. Recommend that the content 
of these offerings include, but not be limited to: 
o Current clinical guidelines for cervical cancer screening, including new 
developments in screening and situations in which the guidelines 
recommended screening less frequently than annually; 
o HPV vaccines, including status of vaccine development and U.S. CDC 
recommendations; and 
o Emerging issues and technologies in prevention, detection and treatment of 
cervical cancer. 
Recommend that the expanded offerings include self-study options, such as on-line 
CME programs. 56 Encourage the Maine Medical Association to conduct outreach 
efforts to promote cervical cancer CME offerings and to inform providers of 
insurance coverage for the HPV vaccine. 
2. Direct MBCHP to review and update the program's clinical guidelines for cervical 
cancer screening, taking into account the most recent guidelines published by the 
American Cancer Society, the American College of Obstetricians and Gynecologists 
and the U.S. Preventive Services Task Force. Direct MBCHP to offer a professional 
education program on this subject after the review and update is complete. 
C. Screening 
ObJective: Increase the number of Maine women who receive cervical cancer screening 
at recommended intervals, with a primary focus on increased screening among women who are 
screened less frequently than recommended, and a secondary focus on decreased screening 
among women who are screened more frequently than recommended. 
56 See for example, existing on-line courses designed by American Society of Colposcopy and Cervical Pathology 
(ASCCP) in collaboration with American Social Health Association (ASHA), 
http://www.asccp.org/edu/home_study.shtml 
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Recommended strategies: 
1. Implement the recommended "public awareness" and "provider knowledge" strategies 
to increase understanding of the importance of screening for cervical cancer and the 
recommended screening intervals. 
2. Expand access to cervical cancer screening for low-inc01ne and underserved women 
as follows: 
a. Expand the MBCHP program to provide cervical cancer screening to women 
under 40 years; the first priority must be to add women ages 35-39 years to the 
program and target services to those women who have never been screened or 
only rarely screened for cervical cancer. 57 
b. Direct the MBCHP to collaborate with the Family Planning Association of 
Maine (FP A) to develop ideas for outreach and coordination to increase 
cervical cancer screening among women ineligible for MBCHP, particularly 
women ages 18-35 years. 
c. Direct the MBCHP to expand its "special screening day" program, at which 
women who are newly enrolled in MBCHP receive their Pap tests and 
1nmnmograms at a single site. 58 Direct MBCHP to consider new locations and 
as well as additional days in existing locations as potential expansion 
strategies. 
d. Direct DHHS, Office ofMaineCare Services, in consultation with MBCHP 
and FP A, to evaluate the possibility of applying for a federal Medicaid Family 
Planning Waiver in order to extend coverage for cervical cancer screening to 
more low-income women in Maine. 
3. Direct the MBCHP in consultation with Maine Comprehensive Cancer Control 
Program, the Maine State Employee Health Commission, the American Cancer 
Society and private insurance companies and to explore options for encouraging 
insured individuals to make and attend medical appointments for cancer screenings, 
including cervical cancer. 59 
4. Direct the Maine Quality Forum (MQF) to identify and assess the status of current 
efforts and initiatives by health insurers and health care providers that may enhance 
the delivery of cervical cancer screening and follow-up care, including but not limited 
to: 
57 Eligibility currently begins at 40 years. 
58 Task Force member, Dr. James A. Raczek, representing the Academy of Family Physicians voted against this 
recommendation. 
59 Examples may include giving employees time off from work for cancer screening appointments. 
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o Computer-based clinical improvement tools designed for health care providers 
to track and manage patient care, including cervical cancer screening. 
o Provider incentives to conduct cervical cancer screening at recommended 
intervals, including health care quality and performance measures. 
D. HPV Vaccine 
Objective: Implement recommendations of the U.S. CDC for the new HPV vaccine. 
Recomnzended strategies: 
1. Make funding for the HPV vaccine a high priority. Specifically, increase state 
funding to the Maine Immunization Program (MIP), including a General Fund 
appropriation. Require that a portion of the appropriation be designated for the HPV 
vaccine, including purchase, distribution and associated operational costs. 
2. Direct the MIP to report to the joint standing committee of the Legislature having 
jurisdiction over health matters regarding program funding and vaccination rates, 
including: 
o The overall program budget for the current year and previous two years, 
including specific information regarding the HPV vaccine expenditures; 
o State and national immunization rates for childhood vaccines, including HPV; 
and 
o An update on the funding gap, specifically the additional funds needed to 
vaccinate 80% of Maine children with CDC recommended vaccines, including 
HPV. 
Require the MIP to submit an initial report no later than January 30, 2008, and a 
follow-up report no later than January 30, 2010. 
3. Direct DHHS to provide coverage under the state MaineCare (Medicaid) program for 
the HPV vaccine consistent with U.S. CDC recommendations. 
4. Integrate HPV vaccine information into "public awareness" and "provider 
knowledge" strategies outlined above. 
20 • Cervical Cancer Prevention, Detection and Education 
E. Further Research and Evaluation 
Objective: Conduct public health research to improve and evaluate cervical cancer 
prevention efforts. 
Recommended strategies: 
1. Direct the Office of Minority Health to work with the Maine Cancer Registry, the 
Maine Comprehensive Cancer Control Program and the Office of Multicultural 
Affairs to examine cervical cancer incidence and prevention issues among racial and 
ethnic minority populations in Maine, including: 
o Available data on cervical cancer among racial and ethnic minorities; 
o Barriers to screening and treatment across different racial and ethnic 
minorities; and 
o Best practices in education and outreach to racial and ethnic minorities. 
2. Direct the Maine Cancer Registry and the Maine Breast and Cervical Health Program 
to examine the geographic variation in cervical cancer rates within Maine, focusing 
on the higher rates of cervical cancer in Washington County and Somerset County 
and why the rates in these locations are higher than in other areas of the state. Direct 
the MCR and MBCHP to collaborate with the American Cancer Society, community 
organizations and health care providers to develop recommendations for reducing the 
incidence of cervical cancer in these counties. 
3. Direct the Maine CDC to monitor and evaluate the state's progress in cervical cancer 
prevention, detection and education in response to the work of the Task Force. 
Require the Maine CDC to review the status and outcome of each Task Force 
recommendation and report its findings and recommendations, including any 
legislation, to the joint standing committee of the Legislature having jurisdiction over 
health services. Require an initial and final evaluation report as follows: 
o Initial report no later than January 30, 2009, and 
o Final report no later than January 30, 2011. 
F. Addendum 
The following two recommendations were made after the final meeting of the Task Force 
and were not endorsed by the group as a whole. 
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1. Direct the Maine CDC to convene a stakeholder group in 2010 to evaluate the 
progress of HPV vaccination in Maine and examine the potential costs and benefits of 
adding the HPV vaccine to the immunizations required for school attendance. 
Require the Maine CDC to report its findings and recommendations to the joint 
standing committee of the Legislature having jurisdiction over health and human 
services matters by January 15, 2011.60 
2. Target additional cervical cancer prevention, detection and education efforts to 
Somerset and Washington Counties as follows: 61 
a. Direct the MBCHP to conduct specific educational outreach initiatives for 
women in Somerset and Washington Counties. 
b. Direct the Maine CDC, working with the Maine Medical Association's 
Committee on Continuing Medical Education, to target medical professionals 
in Somerset and Washington Counties when expanding CME offerings 
regarding cervical cancer (as described under "provider knowledge" 
recommendations). 
c. Prioritize Washington and Somerset Counties in efforts to increase cervical 
cancer screening rates. 
60 Task Force members, Rep. Lisa T. Marrache, Co-Chair of the Task Force, and Dr. Jonathan T. Fanburg, 
representing the American Academy of Pediatrics, made this recommendation. 
61 Task Force member, Dr. Molly Schwenn, Director, Maine Cancer Registry, made this recommendation. 
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APPENDIX A 
Authorizing Legislation, Resolves 2005, Chapter 121 

CHAPTER121 
H.P. 899- L.D. 1302 
Resolve, Establishing The Task Force To Study Cervical Cancer Prevention, Detection and 
Education 
Emergency preamble. Whereas, acts and resolves of the Legislature do not become 
effective until 90 days after adjournment unless enacted as emergencies; and 
Whereas, this resolve establishes the Task Force to Study Cervical Cancer Prevention, 
Detection and Education; and 
Whereas, the study 1nust be initiated before the 90-day period expires in order that the study 
may be completed and a report submitted in time for submission to the next legislative session; 
and 
Whereas, in the judgment of the Legislature, these facts create an emergency within the 
meaning of the Constitution of Maine and require the following legislation as immediately 
necessary for the preservation of the public peace, health and safety; now, therefore, be it 
Sec. 1. Task force established. Resolved: That the Task Force to Study Cervical Cancer 
Prevention, Detection and Education, referred to in this resolve as "the task force," is established; 
and be it further 
Sec. 2. Task force membership. Resolved: That the task force consists of the following 16 
voting members: 
1. Seven members appointed by the President of the Senate as follows: 
A. One member of the Senate; 
B. One representative of a women's health organization; 
C. One communications consultant; 
D. One representative of the American Academy of Pediatrics; 
E. One representative of the American Academy of Family Physicians; 
F. One licensed registered nurse; and 
G. One representative of the Maine Medical Association or its successor; 
2. Seven members appointed by the Speaker of the House of Representatives as follows: 
A. Two members of the House of Representatives; 
B. One representative of the American Cancer Society who is an oncologist; 
C. One representative of the health insurance industry; 
D. One representative of the American College of Obstetricians and Gynecologists; 
E. One member of the Maine Osteopathic Association or its successor; and 
F. One person who has survived cervical cancer; 
3. The medical director of the Maine Cancer Registry or the medical director's designee; and 
4. The Director of the Maine Breast and Cervical Health Program within the Department of 
Health and Human Services, Bureau of Health and other members of the Bureau of Health, as 
A-1 
necessary to the work of the task force, who serve as ex officio nonvoting members of the task 
force. 
When making appointments to the task force, each appointing authority shall ensure that 
appointees reflect the composition of the State's population with regard to ethnicity, race and 
age; and be it further 
Sec. 3. Chair. Resolved: That the Senate member shall serve as chair and the first-named 
House member shall serve as vice-chair; and be it further 
Sec. 4. Appointments; convening of task force. Resolved: That all appointments must be 
made no later than 30 days after the effective date of this resolve. The appointing authorities 
shall notify the Executive Director of the Legislative Council once all appointments have been 
completed. The chair shall call and convene the first 1neeting of the task force by August 1, 
2005; and be it further 
Sec. 5. Quorum. Resolved: That a 1najority of the task force constitutes a quorum for the 
transaction of its business; and be it further 
Sec. 6. Committees. Resolved: That the task force chair may establish committees for the 
purpose of making special studies pursuant to its duties and may appoint persons who are not 
members of the task force to serve on each committee as resource persons. Resource persons are 
voting members of the committees to which they are appointed. Committees may meet with the 
frequency needed to accomplish the purposes of this resolve; and be it further 
Sec. 7. Duties. Resolved: That the task force shall: 
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer in 
Maine; 
2. Review preventive strategies and new technologies, including newly introduced vaccines 
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as their 
relative costs; 
3. Identify and examine the strengths and limitations of existing laws, regulations, programs 
and services regarding coverage and awareness of cervical cancer; 
4. Consider reports and testimony from individuals, local health departments, community-
based organizations, voluntary health organizations and other public and private organizations 
statewide to learn more about their contributions to cervical cancer diagnosis, prevention and 
treatment and their ideas for improving prevention, diagnosis and treatment in Maine; 
5. Develop, in consultation with the Department of Health and Human Services, a statewide 
comprehensive cervical cancer prevention plan and strategies for plan implementation and for 
promoting the plan and awareness of the causes, risk factors, prevention, early detection and 
treatment of cervical cancer to the general public, state and local elected officials and various 
public and private organizations, associations, businesses, industries and agencies; and 
A-2 
6. Recommend strategies for coordination and communication among state and local agencies 
and organizations regarding their involvement in achieving the aims of the cervical cancer 
prevention plan; and be it futiher 
Sec. 8. Staff assistance. Resolved: That the Legislative Council shall provide necessary 
staffing services to the task force; and be it further 
Sec. 9. Compensation. Resolved: That legislative members of the task force are entitled to 
receive the legislative per diem, as defined in the Maine Revised Statutes, Title 3, section 2, and 
reimbursement for travel and other necessary expenses for their attendance at authorized 
meetings of the task force. Public members not otherwise compensated by their employers or 
other entities that they represent are entitled to receive reimbursement of necessary expenses and, 
upon a demonstration of financial hardship, a per diem equal to the legislative per diem for their 
attendance at authorized meetings of the task force; and be it further 
Sec. 10. Report. Resolved: That, no later than December 7, 2005, the task force shall submit 
an initial report to the Joint Standing Committee on Health and Human Services and the 
Governor. The task force is not authorized to meet from December 21, 2005 to April25, 2006 or 
to introduce legislation. The task force shall submit its final report to the joint standing 
committee of the Legislature having jurisdiction over health and human services matters by 
November 1, 2006. The joint standing committee of the Legislature having jurisdiction over 
health and human services matters in the First Regular Session of the 123rd Legislature may 
report out legislation on cervical cancer prevention, detection and education; and be it further 
Sec. 11. Task force funding. Resolved: That the task force shall seek outside funds to fully 
fund all costs of the task force. If sufficient outside funding has not been received by September 
15, 2005 to fully fund all costs of the task force, no meetings are authorized and no expenses of 
any kind may be incurred or reimbursed. Contributions to support the work of the task force may 
not be accepted from any party having pecuniary or other vested interest in the outcome of the 
matters being studied. Any person, other than a state agency, desiring to make a financial or in-
kind contribution must certify to the Legislative Council that it has no pecuniary or other vested 
interest in the outcome of the study. Such certification must be made in the manner prescribed by 
the Legislative Council. All contributions are subject to approval by the Legislative Council. All 
funds accepted must be forwarded to the Executive Director of the Legislative Council along 
with an accounting record that includes the amount of funds, the date the funds were received, 
from whom the funds were received and the purpose of and any limitation on the use of those 
funds. The Executive Director of the Legislative Council shall administer any funds received by 
the task force. The executive director shall notify the chair of the task force when sufficient 
funding has been received; and be it further 
Sec. 12. Appropriations and allocations. Resolved: That the following appropriations and 
allocations are made. 
LEGISLATURE 
Miscellaneous Studies 0444 
Initiative: Provides an allocation of Other Special Revenue Funds in the event outside funding is collected to support 
the activities of the Task Force to Study Cervical Cancer Prevention, Detection and Education. If sufficient outside 
funding has not been received by September 15, 2005 to fully fund all costs of the task force, no meetings are 
authorized and no expenses of any kind may be incurred or reimbursed. 
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OTHER SPECIAL REVENUE 
FUNDS 2005-06 2006-07 
Personal Services $880 
All Other $3,600 
$880 
$3,600 
OTHER SPECIAL REVENUE 
FUNDS TOTAL $4,480 $4,480 
Emergency clause. In view of the emergency cited in the preamble, this resolve takes effect 
when approved. 
Effective June 21, 2005. 
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PO Box 1420 
Ellsworth, ME 04605 
Michael A. Jones M.D. 
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Family Planning Assoc. of ME 
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Waterville, ME 04901 
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Rep. James J. Campbell Sr. 
P.O. Box 29 
West Newfield, ME 04095 
Carrie Bolander, D.O. 
24 Miles Center Way 
Damariscotta, ME 04543 
Bob Downs 
RR 1, Box 1580 
Pittsfield, ME 04967 
Susan Miesfeldt, M.D. 
Maine Center for Cancer Medicine 
100 U.S. Route 1 
Scarborough, ME 04074 
207 885-7600 
Resolve 2005, Ch. 121 
Senate Member 
Representing Communications Consultants 
Representing Licensed Registered Nurses 
Representing the American Academy of Pediatrics 
Representing the Maine Medical Association 
Representing a Women's Health Organization 
Representing the Academy of Family Physicians 
House Members 
House Members 
Representing the Maine Osteopathic Association 
Representing the Health Insurance Industry 
Representing the American Cancer Society (Oncologist) 
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Janet Miles 
PO Box 3205 
Auburn, ME 04212-3205 
James Wilberg, M.D. 
35 Stapleford Drive 
Falmouth, ME 04105 
Medical Director, Maine Cancer Registry 
Dr. Molly Schwenn, Medical Director 
Maine Cancer Registry 
State House Station 11 4th Floor, Key Plaza 
Augusta, ME 04333 
207 287-8945 
Other 
Sharon Jerome Program Director 
MBCHP, Key Plaza, 4th Floor 
11 State House Station 
Augusta, ME 04333 
207 287-6895 
Representing Cervical Cancer Survivors 
Representing the American College of Obstetricians & 
Gynecologists 
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Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
November 16, 2005, 1:00pm to 4:00pm 
Room 427, State House 
AGENDA 
Welcome and Introductions 
Overview of Task Force Legislation, Duties and Requirements 
Where are we now? Overview of Cervical Cancer Incidence and Prevention, 
Detection and Education Initiatives in Maine 
• Dr. Molly Schwenn, Director, Maine Cancer Registry 
• Sharon Gerome, Director, Maine Breast and Cervical Health Program 
Task Force Planning 
• Establishing Priorities and Goals 
• Developing Work Plan I Schedule 
• Planning for Initial Report due December 2005 
Adjournment 










Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
December 16, 2005, 1:00pm to 4:00pm 
Room 427, State House 
AGENDA 
Introductions 
Clinical Guidelines - Dr. Razcek 
Technology Issues- Dr. Jones 
• HPV /vaccine development 
• Thin prep vs. conventional pap 
• Women who are screened but for whom screening fails 
MaineCare coverage of cervical cancer screening/treatment 
Linda Schumacher and Maura Howard, DHHS 
Western Maine Community Action Program, "At Your Cervix" 
Nancy Audet, Program Manager, Tri-County Health Services 
Report Back on the Cervical Cancer Summit, Rep. Marrache 











Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
July 18, 2006, 1:OOpm to 4:00pm 
Room 214, Cross Office Building 
AGENDA 
Introductions 
Review and Updates 
• Review of Initial Report 
• Updates Recent News, Reports and Resources 
Task Force Discussion/Work Session 
• Remaining Duties and Schedule 
• Developing a Statewide Cervical Cancer Prevention Plan- Next Steps 
Break 
Presentation I Maine Health Data Organization - Overview of Available Data 
(Al Prysunka) 
Presentation I Family Planning Association of Maine- Pap Test Data 
(Evelyn Kieltyka) 
Planning for Next Meeting 
Adjournment 
Next Meeting-- August 24, 2006, 9:30am-12:30pm 









Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
August 24, 2006, 9:30am-12:30pm 
Room 214, Cross Office Building 
AGENDA 
Introductions 
Merck I Gardasil 
Maine Immunization Program 
Sally Lou Patterson, Director, Division of Infectious Disease, DHHS 
Family Planning Association I Pap Test Data 
Evelyn Kieltyka, Senior Vice President of Program Services 
Task Force Discussion & Work Session 
Planning for Next Meeting 
Adjournment 
Next Meeting- September 19, 2006, 1:30am-4:30pm 







Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
September 26, 2006, 1 :30-4 :30pm 
Room 214, Cross Office Building 
AGENDA 
Introductions 
Task Force Work Session- Development of Recommendations 
Planning for Next Meeting 
Adjournment 
Meeting - October 17, 2006, 1 :30-4 :30pm 





Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
October 17, 2006, 1 :30-4:30pm 
Room 214, Cross Office Building 
AGENDA 
Introductions 




Draft Legislation to Implement Task Force Recommendations 

An Act to Implement the Recommendations of the Task Force to Study Cervical 
Cancer Prevention, Detection and Education 
Be it enacted by the People of the State of Maine as follows: 
Part A 
Sec A-1. State funding for the human papillomavirus vaccine. Beginning with 
state fiscal year 2006-07, the Maine Legislature shall provide funding to the Maine 
Immunization Program to support the purchase and distribution of the human 
papillomavin1s vaccine and associated program operation costs. The Legislature shall 
appropriate the funds necessary to provide the human papillomavirus vaccine to all 11 
and 12 year old females in the state after utilizing all available federal funding and 
federally-purchased vaccine. 
Sec. A-2. Maine Immunization Program to report on program funding and 
vaccination rates. The Maine Immunization Program shall report to the joint standing 
committee of the Legislature having jurisdiction over health and human services matters 
regarding the status of program funding and vaccination rates. The program shall submit 
an initial report to the committee no later than January 30, 2008, and a second report no 
later than January 30, 2010. Each report must include the following: 
1. Program budget information for the current year and previous two years, 
including specific information regarding expenditures on the human papillomavirus 
vaccine; 
2. Documentation of any funding shortage that exists between available funds 
and the expenditures required to vaccinate 80o/o of Maine children with the human 
papillomavirus vaccine and the other vaccines on the federal Centers for Disease Control 
and Prevention recommended childhood and adolescent vaccine schedule; and 
3. State and national immunization rates for the human papillomavirus vaccine 
and the other vaccines on the federal Centers for Disease Control and Prevention 
recommended childhood and adolescent vaccine schedule. 
Sec. A-3. MaineCare coverage of the human papillomavirus vaccine. The 
Department of Health and Human Services shall amend the rules for the MaineCare 
program to provide coverage for the human papillomavirus vaccine in accordance with 
the federal Centers for Disease Control and Prevention's current recommended childhood 
and adolescent immunization schedule and current recommended adult immunization 
schedule as published in the Morbidity and Mortality Weekly Report. The Office of 
MaineCare Services shall provide information regarding human papillomavirus 
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vaccination among MaineCare members to the Maine Center for Disease Control and 
Prevention for inclusion in the initial and final evaluation reports required under Section 
D-3. 
PartB 
Sec. B-1. Statewide public education campaign regarding cervical cancer. 
The Maine Breast and Cervical Health Program, referred to in this section as "the 
program," shall develop and implement a statewide public education campaign regarding 
cervical cancer prevention and early detection, including the importance of cervical 
cancer screening and the availability of the human papillomavirus vaccine. In carrying 
out the campaign, the program shall: 
1. Broadcast public service announcements, including information about cervical 
cancer prevention and early detection, for all 12 months of the year; 
2. Distribute printed information materials regarding cervical cancer to all sites 
that currently receive program brochures and to additional locations statewide including, 
but not litnited to, libraries, shopping malls, grocery stores, hair salons and health care 
facilities. The program must also offer these informational materials to faith-based 
organizations; 
3. Collaborate with the Office of Minority Health to develop specific outreach 
initiatives for racial and ethnic minority populations in the state. Informational materials 
developed pursuant to subsection 2 must be translated into languages other than English, 
as appropriate; and 
4. Consult with state and local organizations representing senior citizens and 
retired person to develop specific outreach initiatives to reach women over 60 years. 
The program shall report its progress and results in implementing this section to the 
Maine Center for Disease Control and Prevention for inclusion in the initial and final 
evaluation reports required under Section D-3. 
Sec. B-2. School-based cervical cancer education initiatives. The Maine Center 
for Disease Control and Prevention, referred to in this section as "the center," shall 
coordinate the development and implementation of school-based cervical cancer 
education initiatives in accordance with this section. 
1. The center shall develop printed materials on cervical cancer prevention and 
early detection appropriate for students in grades 6-12 and college students to be posted 
at schools and universities. The center shall collaborate with the Maine Department of 
Education and the University of Maine System to coordinate the distribution and posting 
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of materials at public schools and universities. The center shall offer these materials to 
private schools and colleges; 
2. The center shall develop an educational pamphlet regarding the HPV vaccine 
for students in the fifth grade. The center shall collaborate with health education staff 
within the Department of Education, school nurses and health coordinators to facilitate 
the distribution of the pamphlet in public schools. The center shall provide copies of the 
pamphlet to all pediatricians and family physicians licensed in the state and shall offer the 
pamphlet to private schools; 
3. The center shall collaborate with health education staff of the Department of 
Education to develop a listing of medical professionals willing to speak about cervical 
cancer prevention in health education classes or other appropriate forums in public 
schools on a voluntary basis; and 
4. The center shall seek grant funding to implement an activity-based cervical 
cancer educational initiative in schools. The center shall seek input from the Department 
of Education in developing its proposal and applying for grant funding. 
The center shall report its progress and results in implementing this section in the initial 
and final evaluation reports required under section D-3. 
Sec. B-3. Continuing medical education regarding cervical cancer. The Maine 
Center for Disease Control and Prevention shall collaborate with the Maine Medical 
Association's Committee on Continuing Medical Education and Accreditation to identify 
and implement strategies to expand continuing medical education opportunities regarding 
cervical cancer, including but not limited to: current clinical guidelines for cervical 
cancer screening; human papillomavirus vaccines; and emerging issues and technologies 
in cervical cancer prevention, detection and treatment. The Maine Center for Disease 
Control and Prevention shall encourage the Maine Medical Association to conduct 
outreach efforts to promote cervical cancer continuing education offerings to its members 
and inform them of the current status of the human papillomavirus vaccines, including 
availability, cost and insurance coverage. The Maine Center for Disease Control and 
Prevention shall report its progress and results in implementing this section in the initial 
and final evaluation reports required under section D-3. 
Parte 
Sec C-1. Medicaid waiver for family planning services. The Department of 
Health and Human Services, including representatives of the Office of MaineCare 
Services and the Maine Breast and Cervical Health Program, in consultation with the 
Family Planning Association of Maine, Inc., shall examine the potential costs and 
benefits of obtaining a state Medicaid family planning waiver to provide cervical cancer 
screening and related services to individuals who do not otherwise qualify for the state 
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MaineCare program. The examination must include an assessment of the potential value 
of such a waiver to the state's efforts to cervical cancer prevention and early detection. 
No later than January 1, 2008, the department shall make a recommendation to the joint 
standing committee of the Legislature having jurisdiction over health and human services 
matters regarding whether the state should apply to the federal Department of Health and 
Human Services, Centers for Medicare and Medicaid Services for a waiver. 
Sec. C-2. Maine Breast and Cervical Health Program eligibility expansion. 
The Department of Health and Human Services shall amend the rules regarding eligibility 
for the Maine Breast and Cervical Health Program to grant eligibility for cervical cancer 
screening and related services to women ages 35 to 39 years who meet all other eligibility 
criteria for the program. The program shall report its experience under this rule change to 
the Maine Center for Disease Control and Prevention for inclusion in the initial and final 
evaluation reports required under section D-3. 
Sec. C-3. Maine Breast and Cervical Health Program screening initiatives. 
The Maine Breast and Cervical Health Program shall implement the following initiatives 
to increase and improve cervical cancer screening: 
1. The program shall collaborate with the Family Planning Association of Maine, 
Inc., to develop ideas for outreach and coordination to increase cervical cancer screening 
among women who are ineligible for the program, with particular attention to women 
under 35 years of age; 
2. The program shall expand its special screening days. The expansion may 
include adding more sites, adding more screening days at current sites or a combination 
of these strategies, based on the program's assessed need and demand for services; 
3. The program shall update its clinical guidelines for cervical cancer screening, 
based on a review of the most recent clinical guidelines for cervical cancer screening 
published by the American Cancer Society, the American College of Obstetricians and 
Gynecologists and the United States Preventive Services Task Force. The program shall 
offer a professional education program on clinical guidelines for cervical cancer 
screening after it has completed the update; and 
4. The program shall coordinate a stakeholder group including representatives of 
the Maine Comprehensive Cancer Control Program, the State Employee Health 
Commission, the American Cancer Society, and health insurance carriers operating in the 
State to explore options for encouraging insured individuals to make and attend medical 
appointments for cancer screening including, but not limited to, cervical cancer 
screening. 
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The program shall report its progress and results in implementing this section to the 
Maine Center for Disease Control and Prevention for inclusion in the initial and final 
evaluation reports required under section D-3. 
Sec. C-5. Maine Quality Forum review and report on health care system 
initiatives affecting the delivery of cervical cancer screening services. The Maine 
Quality Forum shall identify and assess current initiatives within the state health care 
system that may enhance the delivery of cervical cancer screening and follow-up medical 
care, including computer-based clinical improvement systems to track and manage 
patient care, provider incentives and health care quality and performance measures. The 
forum shall report its findings, and any recommendations, to the Maine Center for 
Disease Control and Prevention for inclusion in the initial evaluation report required 
under section D-3. 
PartD 
Sec. D-1. Cervical cancer incidence and prevention in racial and ethnic 
minority populations. The Office of Minority Health shall, in collaboration with the 
Maine Cancer Registry, the Office of Multicultural Affairs and the Maine Comprehensive 
Cancer Control Program, examine cervical cancer incidence in racial and ethnic minority 
populations in the State and develop recommendations to improve cervical cancer 
prevention and early detection in these populations. The project must consider: 
1. Available data on cervical cancer incidence among racial and ethnic 
minorities; 
2. Barriers to cervical cancer screening and treatment across different racial and 
ethnic minorities; and 
3. Best practices in public health education and outreach to racial and ethnic 
minorities. 
The Office of Minority Health shall report its findings and recommendations to the 
Maine Center for Disease Control and Prevention for inclusion in the initial evaluation 
report required under section D-3. 
Sec. D-2. Geographic variations in cervical cancer rates. The Maine Cancer 
Registry shall, in collaboration with the Maine Breast and Cervical Health Program, 
examine geographic variation in cervical cancer rates within the state, with particular 
attention to the higher rates of cervical cancer observed in Washington County and 
Somerset County, and shall explore reasons for the variation. The Maine Cancer 
Registry and the Maine Breast and Cervical Health Program shall consult with the 
American Cancer Society, community organizations and health care providers to develop 
recommendations for reducing the incidence of cervical cancer in Washington County 
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and Somerset County. The Maine Cancer Registry shall report its findings and 
recommendations to the Maine Center for Disease Control and Prevention for inclusion 
in the initial evaluation report required under section D-3. 
Sec. D-3. Evaluation of cervical cancer prevention, detection and education 
initiatives. The Maine Center for Disease Control and Prevention shall monitor and 
evaluate the State's progress in cervical cancer prevention, detection and education in 
response to the work of the Legislature's Task Force to Study Cervical Cancer 
Prevention, Detection and Education. The center shall submit two evaluation reports to 
the joint standing committee of the Legislature having jurisdiction over health and human 
services matters. The reports must address the progress, status and outcomes of each 
recommendation contained in the final report of the Task Force including, but not limited 
to, each initiative required under this Act. The initial evaluation report must be submitted 
no later than January 30, 2009, and the final evaluation report must be submitted no later 
than January 30, 2011. After review of the initial report, the joint standing committee of 
the Legislature having jurisdiction over health and human services matters may report out 
legislation regarding cervical cancer prevention, detection and education to the First 
Regular Session of the 124th Legislature. After review of the final report, the joint 
standing committee of the Legislature having jurisdiction over health and human services 
matters may report out legislation regarding cervical cancer prevention, detection and 
education to the First Regular Session of the 125th Legislature. 
SUMMARY 
This bill implements the recommendations of the Task Force to Study Cervical 
Cancer Prevention, Detection and Education. 
Part A of the bill relates to the human papillomavirus vaccine. It specifically does 
the following: 
1. It requires the Maine Legislature to provide funding to the Maine 
Immunization Program for purchasing and distributing the human papillomavirus vaccine 
to all 11 and 12 year old females. 
2. It requires the Maine Immunization Program to report to the joint standing 
committee of the Legislature having jurisdiction over health and human matters on the 
status of program funding and vaccination rates, including specific information on the 
human papillomavirus vaccine, by January 30, 2008 and again by January 30, 2010. 
3. It requires the Department of Health and Human Services to amend the rules 
for the MaineCare program to include coverage for the vaccine. 
Part B of the bill relates to improving public awareness and education 
regarding cervical cancer prevention. It specifically does the following: 
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1. It requires the Maine Breast and Cervical Health Program to develop public 
education materials regarding cervical cancer prevention and the human papillomavirus 
vaccine to be distributed to sites that currently receive the program's materials, as well as 
locations that include libraries, malls, health care facilities and others. It requires the 
materials to be translated into languages other than English when necessary. 
2. It requires the Maine Center for Disease Control and Prevention to coordinate 
with the Maine Department of Education and the University of Maine System to develop 
educational materials for schools and universities, including a 5th grade pamphlet. In 
addition, the Center must develop a voluntary speakers group for health and other classes. 
3. It requires the Maine Center for Disease Control and Prevention to collaborate 
with the Maine Medical Association to develop and expand continuing medical education 
units related to cervical cancer, including appropriate screening guidelines and 
vaccination materials. 
Part C of the bill relates to expanding cervical cancer screening opportunities. 
It specifically requires the following: 
1. It requires the Department of Health and Human Services to consult with 
MaineCare, the Maine Breast and Cervical Health Program, and the Family Planning 
Association of Maine to determine the potential costs and benefits of obtaining a federal 
Medicaid family planning waiver to provide cervical cancer screening and related 
services to individuals that do not currently qualify for MaineCare. 
2. It requires the Maine Breast and Cervical Health Program to expand eligibility 
to include women ages 35-39 years who meet all other eligibility criteria for the program. 
3. It requires the Maine Breast and Cervical Health Program to: coordinate with 
the Family Planning Association of Maine to increase cervical cancer screening among 
women under 35 years of ages; expand screening days to new sites or additional days; 
update screening guidelines; and work with the Maine Comprehensive Cancer Control 
Program, the State Employee Health Commission, the American Cancer Society, and 
health insurance carriers to explore options for encouraging people to attend cancer 
screenings. 
4. It requires the Maine Quality Forum to identify and assess current initiatives 
within the state health care system that may enhance delivery of cervical cancer screening 
and follow-up care. 
Part D relates to future research in cervical cancer. It specifically does the 
following: 
1. It requires the Office of Minority Health to collaborate with the Maine Cancer 
Registry, the Office of Multicultural Affairs, and the Maine Comprehensive Cancer 
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Control Program to examine cervical cancer incidence in racial and ethnic minorities in 
the state and study barriers to screening and treatment and best practices for overcoming 
those barriers. 
2. It requires the Maine Cancer Registry to collaborate with the Maine Breast 
and Cervical Health Program to examine the higher incidence of cervical cancer in 
Washington County and Somerset County to determine reasons for the variation and 
develop recommendations for reducing cervical cancer in those counties. 
3. It requires the Maine Center for Disease Control and Prevention to monitor 
and evaluate state progress in implementing the Task Force recommendations and report 
to the joint standing committee of the Legislature having jurisdiction over health and 
human services by January 30, 2009, and again by January 30, 2011. 
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Certain sexually transmitted diseases, including human papillomavirus (1-iPV), hepatitis B (HBV), 
and human imrnunodeficiency virus (HIV)I are associated with cancer. Certain types of HPVI 
specillcally HPV-16 and f-IPV-18, are the major cat!ses of cervical cancer and may also p!ay a role in 
cancers of the anus, vulva, and penis. Hepatitis viruses/ particularly H BV, have been linked 
to liver cancers, and HIV has been linked with lymphoma, anal cancel~ and Kaposi's sarcoma. Risk 
factors for sexually transmitted diseases (STDs) inchtde unprotected sexual contact and multiple 
partners. 
Currently, early detection of certain HPV types, such as HPV-16 and -18 is the standard for 
prevention of cervical cancer. However, with new technologies emerging for HPV-testing, the 
development of effective HPV vaccines, and increased awareness of HPV among the general public, 
there may be more emphasis on primary prevention of cervical cancer. AdditionaiiYr methods used 
to prevent other STDs will have some impact on reducing the incidence of HPV infection and, 
indirectly, the incidence of cervical cancer. 
Objective 1: Reduce by 10% the incidence of sexually transmitted diseases 
associated with the develop1nent of cancer in Maine by 2010. 
Baseline: 12 cases of Acute HBV incidence in Maine, J\!1aine CDC STD Program, 20041 National 
HPV incidence estimate: 6.2 million. 
Strategies 
1. Provide health care/social service professionals w1th at least llve opportunities for l-IPV 
education. 
2. Promote public knowledge about HPV by developing and disseminating at least 500 fact 
sheets for females and health care professionals through collaboration between the Maine 
Breast and Cervical Health Program, the J\!laine Comprehensive Cancer Program and the 
J\11aine HIV, STD and Viral Hepatitis Program. 
3. Increase the number of HIV and STD prevention interventions that target individuzds at high 
risk for HPV, HBV and HJV infection. 
4. Conduct at least two public education campaigns to promote safer sex and/or vaccines by 2010. 
5. Seek funding for HPV vaccination. 
Objective 2: Promote Hepatitis B vaccine for Maine children 19-35 rnonths of age. 
Baseline: 92% received 3 or more doses of hepatitis 13 vaccine, CDC National Immunization Survey, 
2004_ 
Objective 3: Promote Hepatitis B vaccines for at-risk adults accessing STD clinics. 
Strategies 
1 _ Implement at least two interventions annua11y to increase the number of children who receive 
Hepatitis B vaccine by the time they enter kindergarten. 
2. Provide at least two opportunities annually for people working with middle school children 
to learn more about viral hepatitis prevention and resources_ 
3_ Increase the proportion of sexually active adults who receive free Hepatitis B vaccine by 2010_ 
Objective 4: Increase abstinence to 60% a~nong sexually active 9- 12th graders by 
2010 
Baseline: 55%, MYRBS, 2005. 
Objective 5: Increase condotn use at last intercourse to 63% an1ong sexually active 
9- 12th graders by 2010. 
Baseline: 59%, MYRBS, 2005. 
Strategies 
1. Implement Comprehensive School Health Education and a Coordinated School I---lealth 
Program that includes an age appropriate comprehensive sex education curriculum. 
2. Provide sexuality counseling c1nd education. 
3. Provide condoms and full family planning services through high school health center 
grantees. 
4. Conduct public education to promote condom use as a social/community norm. 
5. Seek funding to support and expand efforts. 
ENVIRONMENTAL HEALTH 
About 20 chemicals found in the environment, including arsenic, asbestos, benzene, cadmium, 
chromium, radon, and vinyl chloride, have been identified as known human carcinogens by national 
and international agencies. J\1any additional chemicals have been identified as being potential 
human carcinogens. The cancer burden posed by specific environmental carcinogens (aside 
from occupational exposure) has not been well defined. Despite the fact that the contribution of 
environmental carcinogens to the cancer burden is not as well understood as some of the other 
major causes of cancer, such as tobacco use, preventive measures should be initiated. Such measures 
are largely based on what is known at the present and include the reduction of exposure to 
hazardous chemicals in the workplace and the reduction of environmental pollution. 
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CERVICAL CANCER 
Cervical cancer screening is important to detect signifkant abnormal cell changes that may arise 
before cancer develops. Since the introduction of the Papanicolaou (Pap) test, cervical cancer 
incidence and mortality rates have significantly declined in the United States and in !Vlaine (Figures 
22 & 23). Less than fifty women in J\1aine were diagnosed with cervical cancer in 2005. While the 
number of women affected by cervical cancer is relatively small compared to other cancers, it is one 






Cervical Cancer: Age~Adjusted Incidence Rates, 1995-2002 
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Figure 22: A!Je-Adj1ASted Cervical Cancer Incidence Rates, 1995-2002 
Source: Sumei1lancc, Et>idemiology and Results Pro_qram and the Maine Cancer Registry Program. 
Cervical Cancer: Age-Adjusted Mortality Rates, 1995-2002 
Figure 23: A!Je-Adjusted Cancer lV1ortality Rates, 1995-2002 
SmArcc: National Center for f-lealtf; Stotistics 
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The primary risk factor for cervical cancer is certain types of human papillornavirus (!·-! PV) Other 
risk factors include smoking, poor nutrition, and immunosuppression. 61 Southeast Asian women have 
the highest invasive cervical cancer incidence rates. For example, cervical cancer incidence rates are 
five times higher among Vietnamese American women than white women 62 
Additionally, after the age of 25, the incidence and mortality of invasive cancer in African American 
women increases rapidly with age, while in white women, it rises more slowly. 
Studies have shown repeatedly that early detection is effective in reducing the number of women 
dying of cervical cancer. With routine screening, women significantly improve their odds of 
finding cervical cancer at its earliest and most treatable stages. Several national organizations have 
developed screening guidelines (Appendix D). 
In 2004, almost 89% of Maine women had a Pap test within three years. This is one of the 
highest screening rates for cervical cancer in United States. This is due in part to the successful 
implementation of the Maine Breast and Cervical Health Program, which offers free mammography 
and Pap tests to income eligible women ages 40 and over. Advocacy and education efforts have also 
played an important role. Additionally, al1Iv1aine insurers are required to pay for cervical cancer 
screening, which helps to reduce the financial barrier to getting screened. 
Baseline: 2.1 per 100,000 death\ 1V1aine Cancer Registry, 2002. 
Objective 1: Increase the proportion of Maine women with a uterine cervix who 
have ever received a Pap test to 98% by 2010. 
Baseline: 96(){} of women aged 18 and older with a uterine cervix have ever received a Pap test, 
BRFSS, 2004. 
Strategies 
1. Provide advocacy for ongoing implementation of !Ylaine Breast and Cervical Health 
Program. 
2. Provide advocacy for ongoing funding of Title X (family Planning) activities. 
3. Provide continuing education programs about cervical cancer screening inclusive of HPV 
and vaccine education to health care professionals. 
4. Collaborate with organizations that represent women with a higher prevalence of cervical 
cancer to develop and disseminate culturally and linguistically appropriate messages 
Objective 2: Increase the proportion of Maine women with a uterine cervix that 
received a Pap test within the preceding 1 to 3 years to 92% by 2010. 
Baseline: 899'<> of women aged 18 and older with a uterine cervix have received a Pap test within the 
previous 3 years, BRFSS, 2004. 
Strategies 
1. Provide advocacy for ongoing implementation of Maine Breast and Cervical Health 
Program 
2. Provide advocacy for ongoing funding of Title X (Family Planning) activities. 
3. Provide continuing education programs about cervical cancer screening inclusive of HPV 
and vaccine education to health care professionals. 
4. Collaborate with organizations that represent women with a higher prevalence of cervical 
cancer to develop and disseminate culturally and linguistically appropriate messages. 
Objective 3: Maintain the proportion olpatients diagnosed with invasive cervical 
cancer who receive or have access to appropriate treatment (within 60 days to 
treatn1ent starting) by 2010. 
Baseline: 100% Maine Breast and Cervical Health Program/April 2005 MDE Submission Data 
Quality. 
Strategies 
l. Develop a relationship with cancer treating hospitals to explore the collection of 
data on timely results. 
Objective 4: Reduce the number of women who are diagnosed with regional or 
distant stage cervical cancer by 2010. 
Baseline: 30% Regional and 6(XJ Distant, Maine Cancer Registry, DHHS, 1995-2002. 
Strategies 
I. Conduct case studies of current cancer deaths. 
2. Develop interventions based on the analysis of case studies. 
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